New ‘Trojan Horse’ Cancer Treatment Shows Early Promise in Multiple Tumor Types

February 8, 2019 9:00 am

A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

In patients with advanced, drug-resistant cancers, over a quarter with cervical and … Read more

Drug Treating Breast Cancer May Be Effective in Treating Lung and Ovarian Cancer

February 5, 2019 4:00 pm

Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare … Read more

Antibody That Targets a Protein on the Surface of Stem Cells Also Targets Same Protein on Cancer Cells

January 17, 2019 5:00 pm
An antibody that targets and is taken up only by certain types of cancer cells has been developed by A*STAR researchers. Combining this antibody with an anticancer drug could lead to a new treatment for some types of breast and… Read more

AI Tool Scans Tumour Shape to Detect Aggressive Ovarian Cancer

January 15, 2019 12:30 am

Researchers at The Institute of Cancer Research, London (ICR) have developed an artificial intelligence (AI) test that analyses the shape of tumour cells to identify patients with aggressive ovarian cancer.

The test is intended to enable tailored treatment based on … Read more

Many Americans Unaware of Promise of Targeted, ‘Personalized’ Medicine

December 7, 2018 7:00 pm

By Dennis Thompson

Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.

Former U.S. President Jimmy Carter benefited from one of these

Read more

From Standard to Personalised Care

November 17, 2018 7:00 pm

Woman with ovarian cancer has incredible response to treatment selected based on her tumor molecular profile. This tumor testing is part of the tumor blueprint that Clearity provides.

By Pierre Valette

“It was definitely a ‘holy smokes’ moment,” recounts Justin … Read more

CTLA4 Targeted Therapy Plus PD-1 Targeted Therapy Could Benefit Women With Ovarian Cancer

September 19, 2018 12:22 am

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more

Drug Combination Gives ‘Exciting’ Results in Ovarian and Lung Cancer in Early Trial

August 24, 2018 1:58 am

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more

Taking A Wider View Of Precision Oncology

August 6, 2018 11:06 pm

Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more

Treating Ovarian Cancers by Targeting Mutations

July 31, 2018 11:22 pm

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more

Clinical Trials Offer Promising New Treatments for Ovarian Cancer

February 5, 2018 9:10 pm

By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation

In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more

7 Key Cancer Trends For 2018

January 3, 2018 6:48 pm

By: Elaine Schattner

I expect progress. Here’s my list of major trends and issues that will affect the lives of cancer patients in 2018:

1. Less chemotherapy

recent report finds that among patients with the most common form of … Read more

Tumor Profiling Panel Undergoes Simultaneous FDA, CMS Review

December 9, 2017 12:04 am

The US Food and Drug Administration (FDA) has approved a cancer diagnostic test, FoundationOne CDx (F1CDx, Foundation Medicine), for use in detecting 300-plus genetic mutations in any solid tumor. At the same time, the Centers for Medicare & Medicaid Services … Read more